



PRESS RELEASE

SimuGen launches its flagship software, HT-Stream, as a drug discovery toxicogenomics tool

20 September 2010. London (UK) and Kuala Lumpur (Malaysia)

SimuGen, a venture-backed pharmacogenomics company focused on predicting human toxicity early on in drug discovery, announced today that it has launched its flagship drug discovery toxicogenomics software product HT-Stream (www.ht-stream.com). HT-Stream is an online high throughput screening software tool for analysing complex in vitro data.

Dr Brian O’Keeffe, CEO of SimuGen, commented, “This represents a major milestone in the life of SimuGen. Based on sound computational biology principles and driven by highly sensitive and robust mathematical modelling, HT-Stream is poised to add a whole new dimension to early stage, high throughput safety testing of discovery molecules. The software is easy to use and the whole technology highly scalable. Data-rich decision-making is the key to the future of drug discovery and development at all stages, not least the assessment of toxicity. SimuGen, through the launch of our new HT-Stream software, brings this new data dimension right into the laboratories of all companies involved in the delivery of new, affordable and safer medicines to patients”.

In conclusion Dr O’Keeffe remarked. “Perhaps the real longer-term added value of SimuGen’s technology, lies in its wider applications in areas such as High Content Screening (HCS), mitochondrial toxicity and the effects of metabolites on cellular function under duress, to name a few. SimuGen intends to collaborate intensively with the industry to ensure that the technology lives up to its incredible potential and meets the real needs of our customers”.

Adds Dr Quin Wills, CSO, “For too long we have been caught in the ‘big data’ bubble of omics and high content technologies, only focused on information delivery rather than decision making. HT-Stream helps scientists to use and develop in vitro models that explicitly prioritise their options by utilising prior knowledge, statistical confidence, and result ranking. HT-Stream can be a tool simply to monitor your favourite genes and proteins with great software containing inbuilt data quality control, report generation and collaborative features. Advanced users can set up full screening programmes designed around their own rules-based models. HT-Stream also possesses a growing library of inbuilt toxicity assessment models beginning with liver toxicities such as fatty liver, zone 3 liver necrosis and carcinogenesis to name a few.”

Asia Pacific

Unit T108, Suite 7.01, Level 7
The Gardens South Tower
Mid Valley City
59200 Kuala Lumpur, Malaysia
T +603 2264 5200
F +603 2264 5201

Europe

Suite 405
International House
1- 6 Yarmouth Place
London W1J 7BU
United Kingdom
T +44 (0)2033 264 283

info@simugen-global.com | www.simugen-global.com



SimuGen
intuitive genomics

About SimuGen

SimuGen is a venture-backed pharmacogenomics company focused on predicting human toxicity early on in drug discovery. The company combines traditional, genomic and high content in vitro screening to produce high throughput screens for use alongside other early ADME testing. SimuGen's flagship product, HT-Stream, is online high throughput screening software for analysing complex in vitro data.

More information on SimuGen and HT-Stream can be found on:

www.simugen-global.com and www.ht-stream.com

Asia Pacific

Unit T108, Suite 7.01, Level 7
The Gardens South Tower
Mid Valley City
59200 Kuala Lumpur. Malaysia

T +603 2264 5200
F +603 2264 5201

Europe

Suite 405
International House
1- 6 Yarmouth Place
London W1J 7BU
United Kingdom

T +44 (0)2033 264 283

info@simugen-global.com | www.simugen-global.com